Clinical trials: Nutrition Disorder
Obesity, Overweight or Obesity
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo.
- Trial name
- VESPER-3 (NCT06973720)
- Testing
- MET097
- Where
- 5 sites in United States
- Volunteers
- 268 people
- Sponsor
- Pfizer
Hyperphagia, Prader-Willi Syndrome
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101.
- Trial name
- HERO (NCT06828861)
- Testing
- ARD-101
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 68 people
- Sponsor
- Aardvark Therapeutics, Inc.
Non-alcoholic Steatohepatitis (NASH)
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with…
- Trial name
- NCT04483947
- Testing
- AZD2693
- Where
- 16 sites in United States
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Obesity, Type 2 Diabetes Mellitus in Obese
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM).
- Trial name
- NCT05890950
- Testing
- K-757 and K-833
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- TriGemX Bio, Inc.
Overweight and Obesity
Efficacy of Polyglucosamine for Weight Loss
The polyglucosamine, specification L112 is a medical device and in this clinical trial used for weight reduction of overweight and obese participants.
- Trial name
- NCT02410785
- Testing
- Polyglucosamine
- Where
- 2 sites in Germany, Italy
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
Obesity & Overweight, Type 2 Diabetes
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults
- Trial name
- NCT07539415
- Testing
- DWRX5003, DWC202502, DWC202503
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Overweight
Tolerance Study of the Dietary Supplement Valedia
The objectives of this clinical study are to determine the tolerance of dietary supplement Valedia (blend of plant extracts) through the evaluation of several parameters : Various blood biological parameters for tolerance…
- Trial name
- ECPH1-01 (NCT02790489)
- Testing
- Valedia
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Overweight
Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6
This is a five-part study being conducted to evaluate the safety, tolerability and pharmacokinetics of the HU6 tablet and capsule formulations at steady state in the fed and fasted state for HU6 450 mg once daily (QD) dose (as…
- Trial name
- NCT07170189
- Testing
- HU6
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Rivus Pharmaceuticals, Inc.
COVID-19
Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection
A prospective, longitudinal, observational cohort study looking at patients following COVID-19 disease using multi-parametric magnetic resonance imaging (MRI) to assess the degree and prevalence of organ injury.
- Trial name
- COVERSCAN (NCT04369807)
- Testing
- Outpatient MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 693 people
- Sponsor
- Perspectum
Overweight, Obesity
A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control
This is a randomized, double-blind, placebo-controlled, decentralized clinical trial evaluating the effects of MN Nutra GeLiPthin-1™, a multi-ingredient dietary supplement, on body weight, BMI, waist circumference, appetite…
- Conditions
- Overweight, Obesity, Weight Management, Appetite Control
- Trial name
- NCT07895563
- Testing
- MN Nutra GeLiPthin-1™ Dietary Supplement
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- MNnutra
Obesity
SUCCESS Tracking Study
The overall purpose of this research is to evaluate the long-term outcomes associated with participation in Medifast Direct and Take Shape For Life weight-loss programs in comparison with non-Medifast weight-loss programs.
- Trial name
- NCT01021917
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Medifast, Inc.
Osteoarthritis, Overweight or Obesity
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have…
- Trial name
- ENLIGHTEN-4 (NCT07353931)
- Testing
- Eloralintide
- Where
- 153 sites in United States, Argentina and 12 more
- Volunteers
- 900 people
- Sponsor
- Eli Lilly and Company
Overweight
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
The purpose of this study is to evaluate the safety and efficacy of LMT1-48(Probiotics) compared to a placebo in reducing the body fat in overweight subjects
- Trial name
- NCT03759743
- Testing
- LMT1-48
- Where
- South Korea
- Volunteers
- 97 people
- Sponsor
- Medy-Tox
Cholesterol Lowering
Influence of Polyglucosamine L112 on Serum Surrogate Markers of Cholesterol Absorption
Obesity is widespread and the number of overweight people has tripled from 1975 to 2016. According to the WHO (World Health Organisation), 1.9 billion adults worldwide are overweight, of which 650 million are obese.
- Trial name
- NCT05038436
- Testing
- Polyglucosamine L112
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity.
- Trial name
- NCT07785934
- Testing
- UBT251, Metformin hydrochloride, Warfarin Sodium
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Obesity &Amp; Overweight, Chronic Kidney Disease
UBT251 Injection Phase II Clinical Study (CKD)
This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population
- Trial name
- NCT07134335
- Testing
- UBT251
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Overweight
Efficacy Study for SD Device
The purpose of this study is to determine whether the SD unique device is effective in treatment of overweight and obesity.
- Trial name
- NCT01534325
- Testing
- SD, Control
- Where
- 2 sites in Israel
- Volunteers
- 150 people
- Sponsor
- Beck Medical Ltd.
Metabolism and Nutrition Disorder, Overweight or Obesity
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants…
- Trial name
- STEP 1 (NCT03548935)
- Testing
- Semaglutide
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 1,961 people
- Sponsor
- Novo Nordisk A/S
Morbid Obesity
Six-month Study to Compare the Effects of Volume- and Pressure-Guided Adjustments on Weight Loss and Satiety
The purpose of this protocol is to determine how band fill volumes that are based on intraband pressure readings can influence the comfortability of the band and to compare weight loss with this methodology to weight loss with…
- Trial name
- NCT00960843
- Testing
- Intraband pressure recording system, Conventional Adjustment
- Where
- 2 sites in Australia, Czechia
- Volunteers
- 51 people
- Sponsor
- Ethicon Endo-Surgery
Impaired Fasting Glucose
The Effect of a Nutritional Supplement on Post Prandial Glucose and Lipids in an Adult Population
The primary aim of this study is to evaluate the effect of a fibre rich health food drink on the post prandial glucose and triglyceride peak in healthy overweight adults with impaired fasting glucose (IFG).
- Trial name
- NCT02119325
- Testing
- 25% fibre, 0% fibre
- Where
- India
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.